Literature DB >> 12671285

Excitatory amino acids in epilepsy.

E M Urbanska1, S J Czuczwar, Z Kleinrok, W A Turski.   

Abstract

Epilepsy has been described as a neurological disorder with a prevalence rate estimated at approximately 0.5% of population. In recent years there have been significant advances in our understanding of the contribution of excitatory glutamatergic transmission to seizures. Glutamate appeared to participate in the initiation, propagation and maintenance of epileptic activity. In epileptic patients, changes in glutamate concentration and receptor function were found. Intracerebral or systemic administration of glutamate receptor agonists has become a popular way to induce seizures in rodents. Glutamate antagonists were shown to be potent anticonvulsants in varying experimental seizure models determined genetically, induced chemically and electrically, or due to kindling. A potential therapeutic role for drugs affecting glutamatergic mechanisms in epilepsy has not yet been defined but is constantly attracting interest. In this review we summarize data from studies performed in humans and animals and focus on iono- and metabotropic excitatory amino acid receptor-mediated events in seizures and epilepsy.

Entities:  

Year:  1998        PMID: 12671285

Source DB:  PubMed          Journal:  Restor Neurol Neurosci        ISSN: 0922-6028            Impact factor:   2.406


  11 in total

1.  Influence of convulsants on rat brain activities of alanine aminotransferase and aspartate aminotransferase.

Authors:  M Netopilová; R Haugvicová; H Kubová; J Drsata; P Mares
Journal:  Neurochem Res       Date:  2001-12       Impact factor: 3.996

2.  Oxidative stress induced NMDA receptor alteration leads to spatial memory deficits in temporal lobe epilepsy: ameliorative effects of Withania somnifera and Withanolide A.

Authors:  Smijin Soman; P K Korah; S Jayanarayanan; Jobin Mathew; C S Paulose
Journal:  Neurochem Res       Date:  2012-06-15       Impact factor: 3.996

3.  Influence of proline on rat brain activities of alanine aminotransferase, aspartate aminotransferase and acid phosphatase.

Authors:  N Desai Shanti; K C Shashikumar; P V Desai
Journal:  Neurochem Res       Date:  2004-12       Impact factor: 3.996

4.  Study of epileptiform activity in cerebral ganglion of mud crab Scylla serrata.

Authors:  K K Therisa; P V Desai
Journal:  Invert Neurosci       Date:  2011-01-20

5.  The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury.

Authors:  Carrie A Keck; Hilaire J Thompson; Asla Pitkänen; David G LeBold; Diego M Morales; Jamie B Plevy; Rishi Puri; Boyu Zhao; Marc Dichter; Tracy K McIntosh
Journal:  Restor Neurol Neurosci       Date:  2007       Impact factor: 2.406

6.  Neurobiology, Functions, and Relevance of Excitatory Amino Acid Transporters (EAATs) to Treatment of Refractory Epilepsy.

Authors:  Aleksey V Zaitsev; Ilya V Smolensky; Pascal Jorratt; Saak V Ovsepian
Journal:  CNS Drugs       Date:  2020-11       Impact factor: 5.749

7.  Evaluation of the possible epileptogenic activity of ciprofloxacin: the role of Nigella sativa on amino acids neurotransmitters.

Authors:  Nadia M S Arafa; Mona Abdel-Rahman; Manal F El-khadragy; Rami B Kassab
Journal:  Neurochem Res       Date:  2012-10-21       Impact factor: 3.996

8.  Anticonvulsant drugs, brain glutamate dehydrogenase activity and oxygen consumption.

Authors:  Lourdes A Vega Rasgado; Guillermo Ceballos Reyes; Fernando Vega-Díaz
Journal:  ISRN Pharmacol       Date:  2012-03-08

Review 9.  Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Manuel Merlos; Javier Garzón-Niño
Journal:  Oncotarget       Date:  2016-08-23

10.  Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Javier Garzón
Journal:  Oncotarget       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.